Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.

Authors
Type
Published Article
Journal
Clinical endocrinology
Publication Date
Volume
70
Issue
1
Pages
104–108
Identifiers
DOI: 10.1111/j.1365-2265.2008.03458.x
PMID: 19128367
Source
Medline
License
Unknown

Abstract

We found no evidence of increased mitral valve tenting area/height, valvular thickening or significant regurgitation with the long-term administration of the commonly used doses of cabergoline to treat prolactinoma.

Statistics

Seen <100 times